Details
Stereochemistry | ACHIRAL |
Molecular Formula | C29H35N3O4.C4H4O4 |
Molecular Weight | 605.6781 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CNC(=O)C1=CC=C2C=CN(C3CCN(CCC4=C(OC)C=CC5=C4OC(C)(C)CC5=O)CC3)C2=C1
InChI
InChIKey=MNUJXFRXXTZIIO-WLHGVMLRSA-N
InChI=1S/C29H35N3O4.C4H4O4/c1-29(2)18-25(33)22-7-8-26(35-4)23(27(22)36-29)12-15-31-13-10-21(11-14-31)32-16-9-19-5-6-20(17-24(19)32)28(34)30-3;5-3(6)1-2-4(7)8/h5-9,16-17,21H,10-15,18H2,1-4H3,(H,30,34);1-2H,(H,5,6)(H,7,8)/b;2-1+
Molecular Formula | C29H35N3O4 |
Molecular Weight | 489.6059 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:43:47 GMT 2023
by
admin
on
Sat Dec 16 11:43:47 GMT 2023
|
Record UNII |
DN9H25S82Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
915024-75-8
Created by
admin on Sat Dec 16 11:43:47 GMT 2023 , Edited by admin on Sat Dec 16 11:43:47 GMT 2023
|
PRIMARY | |||
|
DN9H25S82Z
Created by
admin on Sat Dec 16 11:43:47 GMT 2023 , Edited by admin on Sat Dec 16 11:43:47 GMT 2023
|
PRIMARY | |||
|
16038980
Created by
admin on Sat Dec 16 11:43:47 GMT 2023 , Edited by admin on Sat Dec 16 11:43:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Bottom Line: The plasma concentrations inducing 50% RO (EC50) estimated by both direct and effect compartment models were in good agreement.Dose-dependent therapeutic effects of E2110 on dysregulated micturition in different rat models of pollakiuria were also consistently explained by achievement of 5-HT1A RO by E2110 in a certain range ( 60%).Plasma drug concentrations inducing this RO range and EC50 would accordingly be objective indices in comparing pharmacokinetics-RO relationships between rats and humans.
|